title: Metabonomics in the preclinical and environmental toxicity field.
abstract: Preclinical studies assess both efficacy and safety of new drugs through a series of assays used to identify potential target organs and determine safety thresholds. However, despite these efforts, too many drugs prove toxic to humans during clinical phases or later on the market. This paper reviews how metabonomics, one of the key players in systems biology, should be able to assist toxicologists in better predicting the adverse effects of xenobiotics.
authors.affiliation: University of Mons, Department of Human Biology & Toxicology, 20, Place du Parc, 7000 Mons, Belgium. Electronic address: jean-marie.colet@umons.ac.be.
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Colet
mesh_terms: D004353:Drug Evaluation, Preclinical / Q000379:methods*; D064420:Drug-Related Side Effects and Adverse Reactions; D054750:Ecotoxicology / Q000379:methods*; D006801:Humans; D055432:Metabolomics / Q000379:methods*; D049490:Systems Biology; D014116:Toxicology / Q000379:methods; D015262:Xenobiotics / Q000009:adverse effects
chemical_list: D015262:Xenobiotics